Muscle-invasive bladder cancer management is challenging for cisplatin-ineligible patients due to limited treatment options and high recurrence rates. The Padcev-Keytruda combination therapy ...
Throughout October, CURE highlighted research developments and evolving treatment strategies that continue to shape cancer ...
Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...
Hypertension can also raise the risk of other health problems, including kidney disease and dementia. The link between blood ...
The robust 77.8% three-month CR rate observed in the UTOPIA trial is highly encouraging and reinforces the potential of UGN-103 to deliver meaningful benefits to patients,” said Liz Barrett, President ...
Reported three-month complete response rate of 77.8% from the Phase 3 UTOPIA trial of UGN-103, consistent with ENVISION results; FDA agreed to ...
TipRanks on MSN
UroGen Pharma reports Q3 EPS (69c), consensus (68c)
Reports Q3 revenue $27.482M, consensus $32.47M. “Our launch of ZUSDURI, the first and only FDA-approved medicine for adults with recurrent ...
Despite majoring in engineering, a Cranberry Township woman took on a health-related project when applying to graduate school ...
The FMI report, “Bladder Liners Market Size, Share, and Forecast 2025–2035,” projects global revenues to increase by USD 1.18 ...
If you're an individual retail investor searching for healthcare stocks you can buy and hold for at least 20 years, here are ...
Most anglers pack it in for winter, but late-season smallmouths are just heating up. Discover where to find them and the ...
Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 134.1 million in the third quarter of 2025 (Q3 2024: NOK 120.1 million), and an EBITDA of NOK 10.2 million (Q3 2024: NOK 5.0 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback